Core Viewpoint - Novo Nordisk A/S has made an unsolicited bid of at least $6.5 billion for US drugmaker Metsera Inc., initiating a competitive struggle with Pfizer Inc. for a weight-loss drug in a rapidly growing market [1][3] Group 1: Company Actions - Novo Nordisk's offer for Metsera is positioned as superior to Pfizer's previously accepted deal, indicating a strategic move to enhance its market position [1][6] - Pfizer has criticized Novo's actions as "reckless," claiming it seeks to suppress competition and abuse its market dominance [2] - Novo's new CEO, Maziar Mike Doustdar, has implemented significant changes, including job cuts and a $5 billion acquisition of Akero Therapeutics, emphasizing the need for improved execution [4][5] Group 2: Market Context - The obesity market is projected to reach $100 billion by 2030, with Eli Lilly & Co. currently leading, prompting larger pharmaceutical companies to acquire smaller firms like Metsera [3] - Novo's bid for Metsera includes an upfront cash offer of $56.50 per share, potentially rising to $77.75 per share based on performance targets, which is 11% higher than Pfizer's maximum bid of $70 per share [6]